HF Advisory Group LLC Acquires New Position in DexCom, Inc. $DXCM

HF Advisory Group LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 7,205 shares of the medical device company’s stock, valued at approximately $622,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GK Wealth Management LLC bought a new stake in shares of DexCom during the 3rd quarter worth $35,000. Wedmont Private Capital grew its stake in DexCom by 13.9% during the 3rd quarter. Wedmont Private Capital now owns 3,878 shares of the medical device company’s stock valued at $327,000 after acquiring an additional 472 shares in the last quarter. GAMMA Investing LLC grew its position in DexCom by 24.1% during the third quarter. GAMMA Investing LLC now owns 14,266 shares of the medical device company’s stock valued at $1,231,000 after purchasing an additional 2,774 shares in the last quarter. Farther Finance Advisors LLC increased its stake in DexCom by 2.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 10,178 shares of the medical device company’s stock valued at $878,000 after buying an additional 211 shares during the period. Finally, CoreCap Advisors LLC increased its stake in DexCom by 192.2% in the 3rd quarter. CoreCap Advisors LLC now owns 1,791 shares of the medical device company’s stock valued at $155,000 after buying an additional 1,178 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ DXCM opened at $84.11 on Friday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $92.59. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The stock has a market capitalization of $31.74 billion, a PE ratio of 33.25, a P/E/G ratio of 1.41 and a beta of 1.48. The stock has a 50-day simple moving average of $87.54 and a 200 day simple moving average of $75.16.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.09. The company had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%. DexCom’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business earned $0.48 earnings per share. Research analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Royal Bank Of Canada reissued an “outperform” rating and set a $105.00 price objective (up from $90.00) on shares of DexCom in a research report on Thursday, October 1st. Wells Fargo & Company upped their target price on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Barclays raised DexCom to a “strong-buy” rating in a research note on Wednesday. UBS Group set a $96.00 price target on DexCom and gave the company a “buy” rating in a report on Tuesday, July 28th. Finally, Piper Sandler reissued an “overweight” rating and issued a $95.00 price target (up from $88.00) on shares of DexCom in a research note on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, DexCom currently has an average rating of “Buy” and a consensus price target of $91.96.

Insider Transactions at DexCom

In other news, EVP Michael Brown sold 1,700 shares of the business’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $84.04, for a total transaction of $142,868.00. Following the transaction, the executive vice president owned 99,885 shares in the company, valued at approximately $8,394,335.40. The trade was a 1.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jereme Sylvain sold 3,638 shares of the company’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the transaction, the executive vice president directly owned 146,828 shares of the company’s stock, valued at $12,226,367.56. This represents a 2.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 49,313 shares of company stock worth $3,945,875. 0.28% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.